



Systematic Review of Prevalence, their risk factors, evaluation and optimization of potential drug-drug interaction alert rules in NICU

Patel Ayush V.^a, Oza Vrind B.^a, Goswami Chinmay M.^a, Chauhan Raj B.^a, Modiya Digesh R.^{a}*

^aShri Sarvajani Pharmacy College, Gujarat technological university, Near arvind baug, Mehsana, 384001, India.

Corresponding author: - Patel Poonam, Email: pr.poonampatel@gmail.com

ABSTRACT

Drug - drug interactions (DDIs) means a change during a drug's effect on the body when the drug is taken together with a second drug. Drug interaction occurs when a drug's mechanism of action is distributed by the concomitant administration of substances such as foods, beverages or other drugs. Many paediatric patients receive various medicines for his or her treatment and this condition can lead to DDIs. The possibility of PDDI is increased with various medications being prescribed within the hospital for paediatric patients who are admitted to the hospital & their illnesses can even cause physiological changes which affect both pharmacokinetic & pharmacodynamics responses.

Neonatal & critically ill patients are frequently exposed to an oversized number of drugs that increase the prospect of ADE. Risk factors related to PDDIs, the chance in hospitalized children were found to extend with patient age, average number of prescriptions per visit, number of visits, annual diagnosis and groups of medicines. The main risk factor for ADR occurrence within the paediatric population is increase within the number of pharmaceuticals. The prevalence of DDI is influenced by individuals & a number of other risk factors within the population like cohort or polypharmacy likewise because of the nature & number of diseases diagnosed in each patient. However, the prevalence of exposure & prescribing patterns of these clinically significant DDIs in hospitalized children is currently unknown.

Administering medication within the NICU is risky in many other ways thanks to the sensitive nature of neonates, complexity of medications used and challenges of the high-stress NICU environment. More than 70% of hospitals have electronic health records. In typical day, numerous electronic health records. In typical day, numerous electronic alerts are introduced to physicians caring for patients who come to the hospital for the purpose of providing Clinical Decision support (CDs).

Key words :: Drug - drug interactions, Paediatric, Pharmacokinetic, Pharmacodynamics, Neonatal, ADEs, Diagnosis, Polypharmacy, NICU, electronic health records, Clinical Decision support (CDs).

Introduction: -

Drug - drug interactions (DDIs) mean a change during a drug's effect on the body when the drug is taken together with a second drug. Many paediatric patients receive various medicines for his or her treatment and this condition can lead to drug - drug interactions (DDIs). The possibility of potential drug - drug interaction is increased with various medications being prescribed within the hospital for paediatric patients who are admitted to the hospital and their illnesses can even cause physiological changes which are able to further affect both pharmacokinetic and pharmacodynamics responses.

Despite new therapeutic approaches and advances in sympathetic care reflected in enhancement within the standard of lifetime of paediatric oncology patients, the high number of medications conducted during treatment increases the danger of drug-drug interactions. ⁽¹⁾

There are three sorts of drug interactions: Drug-drug interaction: A reaction between two (or more) drugs. Drug-food interaction: A reaction connecting a drug and a food or libation. Drug-condition interaction: A reaction that happens when taking a drug while having a medical condition. For example, taking a decongestant if you have high force per unit area may cause an unwanted reaction Neonates, particularly preterm and preterm neonates (gestational age of but 37 weeks or over 42 weeks), are declared to the Neonatal treatment Unit (NICU) most often thanks to congenital disease.

Neonates and critically ill patients are frequently exposed to an oversized number of drugs that increase the prospect of adverse drug events (ADE). Neonates have physiological characteristics that give to the alteration of the pharmacokinetics within the drugs. DDIs is especially relevant within the

child population, mainly in neonates thanks to physiological immaturity.

Neonates have physiological characteristics that contribute to the alteration of the pharmacokinetics in drugs and might increase the severity of DDIs, including a greater proportion of extravascular total body water, immature renal and hepatic functions, reduced protein concentrations and a comparatively permeable blood brain barrier. Although these characteristics are observed in NICU patients, as far as we all know there aren't any prospective clinical studies evaluating the extent of exposure to potential DDIs. The only real known reference during these people could even be a study by Yeh et al., which supported a retrospective analysis of a database of outpatient prescriptions in neonates and infants. ⁽²⁾

In clinical practice, two or more drugs are combined in such a way that the potency of 1 drug is significantly altered by the presence of the alternative drug. When two drugs are administered together and can have theoretical drug interaction, it can be stated as potential drug - drug interactions (pDDIs). Potential drug - drug interactions are predictable and preventable reasons for drug related adverse events. ⁽³⁾

Clinical trials for safety, dosing and efficacy are lacking although age dependent alterations of pharmacokinetic (PK), drug -drug interactions (DDIs), additionally as intravenous admixture incompatibilities (IAI) may impact on drug efficacy, and this might cause trigger side effects in week.

A literature review study was performed to spot and further assess the danger of relevant DDIs of 48 drugs frequently employed within the tertiary care NICU of the University Hospital of Cologne. Which stated that DDIs were categorized into five different classes per their severity (contraindicated, minor, moderate, and major DDI, IAI), supported the classification utilized within the Micromedex database. Within the database a big interaction is defined as any interaction which can be life threatening and/or demands medical intervention to avoid severe adverse effects. Moderate interactions can cause a degradation of the patient's status and demand an adjustment within the therapy, and minor interactions only have a limited clinical effect. ⁽⁴⁾

Raziyeh Kheshti, et al, A review study identified an incidence of up to 2.8 % of hospital admissions to be caused by ADEs due to DDIs. ⁽⁵⁾

Within the broadest sense , a DDI occurs whenever one drug affects the pharmacokinetics, pharmacodynamics , efficacy or toxicity of another drug reckoning on various factors like drug related (such because the mechanism of action , route of administration , dose , dose interval , duration of treatment , dosing times) and patient - related (such as diagnosis , polypharmacy , pharmacogenetics , length of hospital stays) . ⁽⁶⁾

Adverse drug events (ADE) are the main cause of increased morbidity, mortality and health costs Children admitted to critical care units are more exposed to pharmacotherapy damage risk due to several phases and changes in their development, different response mechanisms to harms and multiple medicines prescription. ⁽⁷⁾

Clinical decision support (CDS) during medication order entry, which is increasingly provided within the Electronic Health Records (EHR), can reduce errors and harm throughout the prescribing process. ⁽⁸⁾

The isolated utilization of such drugs may bring numerous benefits, but the expected therapeutic response could even be sick with the presence of drug interactions. The foremost causes of hospital admissions and mortality are related to drug interactions and their corresponding adverse effects. ⁽⁹⁾

In recent years, several drugs have been withdrawn from the market because of interaction-related adverse events (AEs). Current methods for detecting DDIs rely upon the build-up of sufficient clinical evidence within the post-market stage – a lengthy process that always takes years, during which era numerous patients may suffer from the adverse effects of the DDI. ⁽¹⁰⁾

Drug–drug interactions may cause treatment failure and adverse drug reactions which will complex the course and clinical picture of disease severity. ⁽¹¹⁾

Many DDIs in neonatal treatment unit (NICU) patients can remain unrecognized by considering these various factors similarly because of the workload of the health care professionals. Neonates, particularly admitted to the NICU, have increased the severity of DDIs to end in additional common/severe ADR compared to other populations thanks to physiological/organ immaturity, congenital diseases, birth-related complications, and significant differences in PKs like extravascular total body water, immature renal/hepatic functions, protein concentrations, blood–brain barrier permeability. ⁽³³⁾

Prevalence and their risk factors: -

In epidemiology, prevalence is the proportion of a selected population found to be plagued by a medical condition at a selected time. Within the paediatric population, the prevalence of potential DDIs ranges from 3.8% to 75%.

With relevancy risk factors related to potential DDIs, the chance in hospitalized children was found to extend with patient age, average number of

prescriptions per visit, number of visits per annum, some diagnoses (epilepsy, leukaemia, rheumatoid arthritis) and groups of medicine (antiepileptic, anti-neoplastic, systemic antifungal and immunosuppressant drugs, also as those used for tract obstructive conditions).

In step with study conducted in paediatric patient potential DDIs are related to Caucasian ethnicity, some diagnoses (neoplasms, diseases of the vascular system, congenital anomalies and diseases of the system), presence of complex chronic conditions, increases daily exposure to drugs and increases PICU retention days. ⁽¹²⁾

Development of medication in paediatric diseases is restricted and lots of authentic drug-based treatments are rarely recommended. Appropriately, off-label use of medicine in paediatricians is normal.

So, in paediatric patients drug-drug interactions (DDIs) effects are produced. Appropriately, uncertainty arises between both treatment effects and adverse effects. Exposure could be a well-known risk factor for adverse events in an increasing number of medicines and it's been described as a risk factor for paediatric patients within the hospital setting. ⁽¹³⁾

Some risk factors & prevalence of DDI influence the manifestation of DDIs in populations, like cohort or polypharmacy additionally because of the nature and number of diseases diagnosed in each patient. ⁽¹⁸⁾

The main risk factor for adverse drug reaction occurrence within the paediatric population is the increase within the number of pharmaceuticals. ⁽¹⁾

DDIs also are more frequent in hospitalized patients who have longer hospital stays and receive more medications per day. Hospitalized patients are more likely to be plagued by DDIs thanks to severe and multiple illnesses, comorbid conditions, chronic therapeutic regimens, poly-pharmacy, and frequent modification in therapy. Medically, DDIs can cause potentially harmful outcomes for patients and lead to an estimated cost of quite \$1 billion p.a. in government health savings accounts. ⁽¹⁴⁾

Clinical decision keeping systems (CDSS) aim to extend the protection of a drug therapy. They typically contain an information module on co-medication with a drug - drug interaction (DDI) screening tool and several DDI screening tools, with various severity. DDIs doesn't seem to be always related with ADRS, and different patients react individually to DDIs, which is why the term "potential DDI "usually wants to relate them." Potential DDIs " are DDIs which might - but don't always cause ADRs. ⁽¹⁵⁾

The causes and significance of drug interactions are complicated and include drug dose, serum drug level, route of administration, drug metabolism, duration of therapy, and patient factors, like age, gender, weight and genetic predisposition.

The aim of identifying these DDIs was to prioritize clinical care and research of DDIs in hospitalized children. A similar prioritization of DDIs in adults by national patient advocacy organizations has been accustomed to developing safety protocols for health care systems.

However, the prevalence of exposure and prescribing patterns of these clinically significant DDIs in hospitalized children is currently unknown. Medications with DDIs are often categorized by the severity of a possible DDI, rather than risk grade, by using drug classification DDI software.

Evaluation of paediatric drug-drug interactions: -

Evaluation of drug interactions almost, by means of panels of physicians, pharmacists, and pharmacologists, to gauge the literature critically and indicate the clinical importance of reported drug interactions. Paediatric drug-drug interactions (DDIs) are often life intimidating, and a thought for evaluating the interaction potential should be a part of every paediatric drug evolution program. Children are exposed to several medications during hospitalization that predispose them to experience DDIs. ⁽¹⁶⁾

DDIs are a heavy concern in pharmacopeia during which the pharmacological effect of a drug is exaggerated or suppressed by co-administration of the offending drug. DDI effects can manifest as variable adverse effects of pharmacology depending on the extent, including both on- and off-target effects. Methodological thought Instead, suppression of a drug's pharmacological effect may cause treatment failure. Generally, a DDI can have a therapeutic benefit and has been deliberately accounted for within the recommended dosing regimen. ⁽¹⁷⁾

These DDIs can conduct to extend in lucrative burden on health-care system with the chance to health of patient. Improvements in hospital stay also expand bed occupancy in hospitals and may extend morbidity and mortality among patient population. This hints that DDIs jeopardize the patient safety aspect. ⁽³⁾

Accordingly, Feinstein et al. A cohort study of paediatric and teenage patients within the US found a prevalence of drug–drug interactions of 49%. Despite the differences within the number of patients involved and within the forms of hospital services included in both the Feinstein et al. and Getachew et al. studies, prevalence of drug interactions in paediatric populations remains similar. This might suggest that no matter the country and socioeconomic situation, the prevalence of pDDIs is near 50%.⁽¹⁸⁾

Consequences of patients in numerous paediatric medical care units (PICU) can't be interpreted without risk adjustment. Intensity of illness is also associated in terms of a disease stage classification using physiological scores.⁽¹⁹⁾

There is scant data on DDIs and pharmacokinetics profiles in the paediatric population due to ethical and practical obstruction. The results of a paediatric database analysis within the US showed that approximately half hospitalized children were exposed to a possible DDI, of which 41% were considered 'major' per the Micromedex DRUG-REAX system.

The prevalence of potential DDIs was also investigated in children admitted to emergency departments and it had been reported to be as high as 61%. Moreover, studies performed on adult populations extrapolated to the paediatric population may end in under or over prediction of the severity of DDIs. The foremost common diagnoses were respiratory diseases, infectious diseases were also commonly encountered in children, and anti-infective agents and medicines utilized within the respiratory system and central nervous system were the foremost drug classes involved in C and D interactions.⁽¹⁾

However, on condition that paediatric studies often employ an opportunistic study design, estimation of the DDI magnitude in paediatric age groups is challenging. Selection of an appropriate modelling approach is required and should rely on the supply and/or informativeness of clinical DDI data. Hospitalized paediatric patients often receive multiple drugs, resulting in a possible increased DDI risk.

Daniel Gonzalez, Jaydeep Sinha authors found that out of 498,956 hospitalizations in 2011, 49% were associated with ≥ 1 potential DDI. Also, they identified that in 41% of these hospitalizations, paediatric patients were exposed to a "major" potential DDI (defined as a DDI that's life-threatening or requires medical intervention to treat or prevent an adverse drug event).⁽³¹⁾

It's important to know the thanks to do a full and thorough neonatal examination and identify common findings. A scientific approach, ideally completing the identical order of physical examinations for each infant, will ensure appropriate milestones within the physical examination.

Neonates, especially preterm infants, are relatively immunocompromised thanks to immaturity of the system moreover as decreased placental passage of maternal antibodies. Here we highlight a variety of the components of the neonatal system that are immature and contribute to increased susceptibility to serious bacterial, fungal, and viral infections. a spread of interventions to decrease rates of neonatal sepsis are studied, including postnatal use of lactoferrin, anti-staphylococcal monoclonal antibodies, intravenous immunoglobulin (IVIG), granulocyte-macrophage colony stimulating factors, probiotics, glutamine and fluconazole prophylaxis for invasive candida infection.⁽³²⁾

Optimization of paediatric drug-drug interaction: -

Safe treatment with any drug based on understanding how that drug is metabolized, cleared, and interacts with its primary target. For each of these factors, Newborns can vary markedly from older children and adults. For this reason, extrapolating safety and efficacy of a drug in critically ill newborns supported data collected in older children and adults are often inexact. Additional, important considerations that directly affect safe drug administration in neonates have often been overlooked or underemphasized.⁽³⁴⁾

Several factors may have influenced the changes in medication use observed over time. An increasing number of studies investigating safety and pharmacokinetic properties of specific molecules have led to a far better understanding of their effects within the target population.⁽³⁵⁾

Despite advances in neonatal medicine, infants requiring neonatal treatment still experience substantial morbidity and mortality. The aim of this initiative was to return with large-scale simultaneous improvements in multiple domains of care in an exceedingly large neonatal network through a program called the "100,000 Babies Campaign".⁽³⁶⁾

Warfarin use has increased dramatically over the past 2 decades and keeps with the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System, warfarin is one all told the best 10 drugs associated with serious adverse events. Furthermore, bleeding complications from warfarin are implicated in the foremost common drug-related events in emergency departments.⁽³⁷⁾

Furthermore, many guidelines are focused on modality and do not seem to be relevant to patients with multiple conditions that sometimes occur with patients in need of opioid medication. The net result is that just about all of these guidelines aren't very applicable to a significant portion of patients

requiring opioid analgesia, who could even be taking multiple medications for multiple conditions, and who may potentially be in peril for DDIs. DDIs involving opioids may cause significant morbidity and mortality, also because of the potential for increased healthcare utilization and costs.⁽³⁸⁾

Alert rules in Neonatal Intensive Care Unit (NICU): -

Administering medication within the NICU is risky in many other ways thanks to the sensitive nature of neonates, the complexity of the medications used, and therefore the challenges of the high-stress NICU environment. Neonatal medications are universally weight based, requiring calculations for every dose.

Very few medications are available in neonatal dosage forms or concentrations from pharmaceutical manufacturers. High-alert medicine may be a variety of medicine that, when utilized in error, puts patients at high risk of some significant adverse event. The Institute for Safe Medication Practice (ISMP) defines an inventory of all drugs classified as high alert and updates the information annually with a special target agonists and adrenergic antagonists, antiarrhythmic, antithrombotic drugs, drugs, opioids, sedatives, concentrated electrolytes. As such NICU nurses solely rely upon standardized patient wristbands for identification purposes.⁽²⁰⁾

Drug-drug interaction alerting with commercial EHR software isn't any longer limited to early adopters. While it's been known for over a decade that drug interaction and allergy alerts were met with a high override rate, the importance of this study lies within the finding that trading EHRs as federally required to fulfil core significant Use impartial haven't managed to boost this issue.⁽²¹⁾

To scale back the likelihood of alert fatigue, Consensus of All recommends reducing the quantity of ineffective alerts by analysing alert metrics and perceived satisfaction of alerts.⁽²⁸⁾ Currently, there's no specific solution for implementing DDI warnings or a way to display them. Opportunities to boost DDI alerting include using differential display supported DDI severity, establishing revised lists of medically significant DDIs, and thoroughly reviewing institutional implementation decisions associated with DDIs.⁽²²⁾

The alerting system may contain error-producing conditions like low cytotoxicity, low sensitivity, uncertain information content, inessential workflow disruptions, and unsafe and inefficient handling. These may lead to active failures of the physician, like disregarding alerts, misinterpretation, and incorrect handling. Efforts to reinforce patient safety by increasing correct handling of drug safety alerts should specialize in the error-producing situation in software and association.⁽²³⁾

Clinical Decision Supports (CDS) alerts are occurring with increasing use of EHRs. Seven key elements (terminology, symbols/icons, colour, minimal text, formatting, content, and reporting standards to facilitate usability) should be included with the DDI decision base. DDI information should be granted to any or all physicians. Finally, in their ongoing form, override rates have limited capability to assess warning potency.⁽²⁴⁾

The marked increase in alert acceptance looks promising and may be further evaluated after hospital wide implementation.⁽²⁵⁾

Targeted DDI alert reductions reduce alert burden overall, and enlarge net efficiency as sustained by think time for all prescribers better than for non-prescribers.⁽²⁶⁾

The incidence of DDI and therefore the alert-override rate contradicts by the admitting department. The ED and ICU were corresponding with higher risks for alerts on DDI than did the GW after rearranging for other known risk factors.⁽²⁷⁾

A June 2011 review of the dashboard prototype revealed that providers and pharmacists were experiencing a high prevalence of two DDI alerts for benzodiazepines and trace-ingredient ethanol. In the event that team members disagreed upon the clinical significance of their assigned DDI, the alert rule was presented to the whole clinical pharmacy group for discussion until a concord agreement was reached. Any controversial warnings were discussed with the physician group that may presumably encounter the DDI warning to confirm that the foremost likely end users agreed on the important warning regarding the alerts' significance.

for instance, the potassium- sparing diuretics and potassium supplements DDI alert rule was discussed among the Divisions of Cardiology and Nephrology and determined to be of clinical significance; this alert remains a full of life, interruptive responsive to encourage providers to watch serum potassium levels. All recommendations were then presented to the CDS committee for approval.⁽⁸⁾

Conclusion

The electronic health record (EHR) collects clinical support in a computerized prescriber system, and it has been identified as one of the interventions with the greatest potential to reduce medication errors and related harm in the paediatric inpatient setting^(28, 8).

So that clinicians and individuals can provide personalized information that is intelligently filtered to improve health care delivery⁽²⁸⁾.

More than 70 percent of hospitals in the US have electronic health records. In the course of a typical day, numerous electronic alerts are introduced to physicians caring for patients who come to the hospital for the purpose of providing CDs⁽²⁹⁾.

We have shown that it is possible to safely reduce the medication alert burden by consistently deactivating clinically irrelevant alert rules while concurrently monitoring for medication-associated harm. Hospitals may find administering a dashboard like ours useful when performing quality advance customization of medication alert rules and developing a prospective strategy for alert management⁽⁸⁾.

We identified a limited number of medications that were represented within the majority of potential interactions. Interactions that may result in a reduced treatment effect constituted approximately half D-interactions, and a 3rd of C-interactions. The frequency of potential interactions was higher in older children.⁽¹³⁾

Multiple regression analyses suggested the association of more severe pDDIs with a rise of PICU length of stay.⁽⁷⁾

Potential drug-drug interactions were common within the paediatric patients studied, whereas the frequency of real drug-drug interactions was low. However, some drug-drug interactions required medical actions additionally to routine monitoring. More information is required on real drug-drug interactions as those associated with failed efficacy can be underestimated. The prevalence of potential DDIs within the ED is high, and techniques should therefore be established to watch patients' safety during their stay, additionally to conducting investigations to estimate the real harm potential DDIs inflict on patients.⁽¹²⁾

It is noteworthy that a major number of medications causing potential drug-drug interactions are prescribed together in paediatric clinics. Increasing the attention of physicians on this issue will prevent potential complications and ensure patient safety.⁽³¹⁾

Patients hospitalized at US children's hospitals are commonly exposed to medications with clinically significant DDIs. Exposure risk varied substantially across hospitals. Further study is needed to work out the speed of adverse events because of DDI exposures and factors compliant for interventions promoting safer medication use.⁽³⁰⁾

REFERENCES

1. Berna Terzioğlu Bebitoğlu, Elif Oğuz, Ajla Hodzic. Evaluation of potential drug-drug interactions in a pediatric population. *Turk Pediatri Ars.* 2020; 55(1): 30–38.
2. Haline Tereza Costa, Ramon Weyler Duarte Leopoldino, Tatiana Xavier da Costa, Antonio Gouveia Oliveira, Rand Randall Martins. Drug-drug interactions in neonatal intensive care: A prospective cohort study. *Pediatric Neonatal* 2021 Mar;62(2):151-157.
3. Simran Patel, Mayur Chaudhari, Nrupal Patel. Evaluation of potential drug-drug interaction in indoor patients of the pediatric department of tertiary care hospital. *National Journal of Physiology Pharmacy and Pharmacology* 2019;9(10):1012-1016.
4. Kai ROSEN, Martin H. WIESEN, André OBERTHÜR, Guido MICHELS, Bernd ROTH, Cornelia FIETZ, Carsten MÜLLER. Drug-drug interactions in Neonatal Intensive Care Units: how to overcome a challenge. *MINERVA MEDICA* 2021;73(2):188-97.
5. Raziye Kheshti, Mohammadsadegh Aalipour, Soha Namazi. A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. *Journal of research in pharmacy practice* 2016;5(4):257–263.
6. Nadir Yalçın, Merve Kaşıkçı, Murat Yurdakök. Novel Method for Early Prediction of Clinically Significant Drug- Drug Interactions with a Machine Learning Algorithm Based on Risk Matrix Analysis in the NICU. *MDPI* 2022; 11 (16):4715.
7. Elisangela da Costa Lima, Barbara Dias Camarinha, Luciane Cruz Lopes. Severe Potential Drug-Drug Interactions and the Increased Length of Stay of Children in Intensive Care Unit. *Front Pharmacol* 2020; 11:555407.

8. Allan F Simpao, Luis M Ahumada, Bimal R Desai, Christopher P Bonafide, Jorge A Gálvez, Mohamed A Rehman, Abbas F Jawad, Krisha L Palma, Eric D Shelov. Optimization of drug– drug interaction alert rules in a pediatric hospital's electronic health record system using a visual analytics dashboard. *Journal of the American Medical Informatics Association* 2015;22(2):361–369.
9. Jacqueline Martinbiancho, Joice Zuckermann, Mariane M. Silva. Profile of drug interactions in hospitalized children. *Pharm Pract (Granada)*. 2007 Oct-Dec; 5(4): 157–161.
10. Aurel Cami, Shannon Manzi, Alana Arnold, Ben Y. Reis. Pharmacology Interaction Network Models Predict Unknown Drug-Drug Interactions. *PLoS One*. 2013; 8(4).
11. Emanuella de Souza Ribeiro, Sybelle Christianne Batista de Lacerda Pedrosa. Evaluation of potential drug interactions in hospitalized pediatric oncology patients. *Mundo da Saúde* 2021, 45: 034-044.
12. Olga Morales-Ríos, Luis Jasso-Gutiérrez, Alfonso Reyes Lopez, Juan Garduño-Espinosa, Onofre Muñoz-Hernández. Potential drug-drug interactions and their risk factors in pediatric patients admitted to the emergency department of a tertiary care hospital in Mexico. *PLoS One*. 2018.
13. Johan Holm, Birgit Eiermann, Elin Kimland, Buster Mannheimer. Prevalence of potential drug-drug interactions in Swedish pediatric outpatients. *PLoS One*. 2019; 14(8).
14. Wondim Ayenew, Getahun Asmamaw, and Arebu Issa. Prevalence of potential drug-drug interactions and associated factors among outpatients and inpatients in Ethiopian hospitals: a systematic review and meta-analysis of observational studies. *BMC Pharmacol Toxicol*. 2020.
15. Ly Wen Dieuab, Anne B. Leuppi-Taegtmeier, John van den Anker, Daniel Trachsel, Verena Gottabe. Prevalence of high-risk drug-drug interactions in pediatric inpatients: a retrospective, single-center cohort analysis. *Swiss Med Wkly*. 2019; 149.
16. Sara N. Salerno, Gilbert J. Burckart, Daniel Gonzalez. Public Access Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities. *Clin Pharmacol Ther*. 2019 May; 105(5): 1067–1070.
17. Daniel Gonzalez, PharmD, Jaydeep Sinha. Public Access Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations. *J Clin Pharmacol*. 2021 Jun; 61(Suppl 1): S175–S187.
18. Fabiola Medina-Barajas, Estefanía Vázquez-Méndez, Edsául Emilio Pérez-Guerrero, Iván I. Hernández-Cañaveral, Real-Ornelas Gabriel A, Selene G. Huerta-Olvera Sho. Pilot study: Evaluation of potential drug–drug interactions in hospitalized pediatric patients. *Pediatr Neonatal* 2020 Jun;61(3):279-289.
19. Ahmed El-Nawawy Evaluation of the Outcome of Patients Admitted to the Pediatric Intensive Care Unit in Alexandria Using the Pediatric Risk of Mortality (PRISM) Score. *Journal of Tropical Pediatrics*, April 2003;49(2)109–114.
20. John Rene Labib, Meray Rene Labib Youssef, Shaimaa A.M. Abd El Fatah. High alert medications administration errors in neonatal intensive care unit: A pediatric tertiary hospital experience. *Turk J Pediatr* 2018; 60(3):277-285.
21. A.D. Bryant, G.S. Fletcher, T.H. Payne. Drug interaction alert override rates in the Meaningful Use era. *Appl Clin Inform*. 2014; 5(3): 802–813.
22. Dustin S McEvoy, Dean F Sittig, Adam Wright. Variation in high-priority drug-drug interaction alerts across institutions and electronic health records. *J Am Med Inform Assoc*. 2017 Mar; 24(2): 331–338.
23. Heleen van der Sijs, Jos Aarts, Marc Berg. Overriding of Drug Safety Alerts in Computerized Physician Order Entry. *J Am Med Inform Assoc*. 2006 Mar-Apr; 13(2): 138–147.
24. Thomas H Payne, Lisa E. Hines, Raymond C Chan, Seth Hartman, Joan Kapusnik-Uner, Alissa L Russ, Bruce W Chaffee, Christian Hartman, Victoria Tamis, Brian Galbreth, Peter A Glassman, Shobh Phansalkar, Heleen van der Sijs, Sheila M Gephart, Gordon Mann, Howard R Strasberg, Amy J Grizzle, Mary Brown, Gilad J Kuperman, Chris Steiner, Amanda Sullins, Hugh Ryan, Michael A Wittie, Daniel C Malone. Recommendations to improve the usability of drug–drug interaction clinical decision support alerts. *J Am Med Inform Assoc* 2015 Nov; 22(6):1243-50.
25. Pieter Cornua, Stephane Steurbaut, Kristof Gentens, Rudi Van de Velde, Alain G. Dupont. Pilot evaluation of an optimized context-specific drug–drug interaction alerting system: A controlled pre-post study. *Int J Med Inform* 2015 Sep;84(9):617-29.

26. Richard Schreiber, Julia A.Gregoire, Jacob E. Shaha MStat, Steven H.Shaha. Think time: A novel approach to analysis of clinicians' behavior after reduction of drug-drug interaction alerts. *Int J Med Inform* 2017 Jan; 97: 59-67.
27. Eun Kyoung Ahn, Hye Jin Kam, Dong Kyun Park, Eun Young Jung, Youngho Lee, Rae Won Park. Differences among admitting departments in alerts and alert overrides for drug– drug interaction. *Pharmacoepidemiol Drug Saf* 2014 Apr; 23(4):390-7.
28. Calvin C. Daniels, Jonathan D. Burlison, Donald K. Baker, Jennifer Robertson, Andras Sablauer, Patricia M. Flynn, Patrick K. Campbell, James M. Hoffman. Optimizing Drug Drug Interaction Alerts Using a Multidimensional Approach *Pediatrics* 2019 Mar.
29. Judith W Dexheimer, Eric S. Kirkendall, S. Andrew Spooner. The Effects of Medication Alerts on Prescriber Response in a Pediatric Hospital. *Appl Clin Inform.* 2017 Apr; 8(2): 491–501.
30. James W. Antoon, Matt Hall, Derek J. Williams. Prevalence of Clinically Significant Drug Drug Interactions AcrossUS Children's Hospitals *Pediatrics.* 2020 Nov; 146(5).
31. Daniel Gonzalez, Jaydeep Sinha Pediatric Drug-Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations *J Clin Pharmacol* 2021 Jun;61 Suppl 1(Suppl 1):S175-S187.
32. Andres Camacho-Gonzalez, Paul W. Spearman, Barbara J. Stoll Neonatal Infectious Diseases: Evaluation of Neonatal Sepsis *Pediatr Clin North Am.* 2013 Apr; 60(2): 367–389.
33. Nadir Yalçın, Merve Kaşıkçı, Hasan Tolga Çelik, Karel Allegaert, Kutay Demirkan, Şule Yiğit, Murat Yurdakök Novel Method for Early Prediction of Clinically Significant Drug–Drug Interactions with a Machine Learning Algorithm Based on Risk Matrix Analysis in the NICU *J Clin Med* 2022 Aug 12;11(16):4715.
34. Gary J Noel, John N Van Den Anker, and Donald Lombardi, Robert Ward Improving drug formulations for neonates: making a big difference in our smallest patients. *J Pediatr* 2012 Nov; 161 (5):947-9.
35. Emily M. Hsieh, Christoph P. Hornik, MD, P. Brian Smith Medication use in the neonatal intensive care unit *Am J Perinatol* 2014 Oct;31(9):811-21.
36. Dan L Ellsbury, Reese H Clark, Robert Ursprung, Darren L Handler, Elizabeth D Dodd, Alan R Spitzer. A Multifaceted Approach to Improving Outcomes in the NICU: The Pediatrix 100 000 Babies Campaign *Pediatrics* 2016 Apr; 137 (4).
37. Marie A. Yu, Jolene R. Bostwick, Ilze Sturis Hallman. Warfarin Drug Interactions: Strategies to Minimize Adverse Drug Events *np journal* 2021 June; 7(6):P506-512.
38. Gilbert J. Fanciullo, Tabitha Washington. Best Practices to Reduce the Risk of Drug-Drug Interactions: Opportunities for Managed Care. *Am J Manag Care* 2011 Sep; 17 Suppl 11:S299-304.